Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and Camrelizumab +/- Radiotherapy in Oligometastatic Esophageal Cancer
NCT05183958Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05183958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183958.